HIGHLIGHTS
SUMMARY
In recent years, interest in SP in oncology has been growing due to the high prevalence of SP (15-74%) in cancer patients. Attention to SP has grown in the field of radiotherapy (RT), given the evidence of the significant impact of SP on the prognosis of RT-treated patients, and the possibility of preventing and at least partially treating this syndrome. Three consensus statements agreed to define SP as a syndrome characterized by age-associated loss of skeletal muscle mass (quantitative impairment) and function (qualitative impairment) combined or not with increased fat mass . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.